Barbara A Conley1, John J Wright, Shivaani Kummar. 1. Division of Hematology/Oncology, Department of Medicine, College of Human Medicine, B414 Clinical Center, Michigan State University, East Lansing, Michigan 48824, USA. barbara.conley@hc.msu.edu
Abstract
BACKGROUND: Alterations in chromosome structure play critical roles in the control of gene transcription. These "epigenetic" alterations include modification of histones and other proteins by acetylation and/or phosphorylation. Normally, these modifications are balanced finely and are highly reversible in normal tissues, but they may be imbalanced and heritable in tumor cells. Histone deacetylase inhibitors increase histone acetylation, thereby modulating the expression of a subset of genes in a coordinated fashion. Several tumor suppressor genes associated with the malignant phenotype are repressed by epigenetic mechanisms in sporadic cancers. Thus, therapy with histone deacetylase inhibitors may alter tumor phenotype to inhibit growth in such tumors. METHODS: The authors reviewed the rationale for histone deacetylase inhibitors as potential anticancer agents and reviewed some preclinical and early clinical trial data with various classes of histone deacetylase inhibitors. RESULTS: Preclinical and clinical antitumor activity has been observed. Toxicities include fatigue, myelosuppression, and cardiac abnormalities. CONCLUSIONS: Histone deacetylase inhibitors have shown promising activity in some solid tumors and hematologic malignancies.
BACKGROUND: Alterations in chromosome structure play critical roles in the control of gene transcription. These "epigenetic" alterations include modification of histones and other proteins by acetylation and/or phosphorylation. Normally, these modifications are balanced finely and are highly reversible in normal tissues, but they may be imbalanced and heritable in tumor cells. Histone deacetylase inhibitors increase histone acetylation, thereby modulating the expression of a subset of genes in a coordinated fashion. Several tumor suppressor genes associated with the malignant phenotype are repressed by epigenetic mechanisms in sporadic cancers. Thus, therapy with histone deacetylase inhibitors may alter tumor phenotype to inhibit growth in such tumors. METHODS: The authors reviewed the rationale for histone deacetylase inhibitors as potential anticancer agents and reviewed some preclinical and early clinical trial data with various classes of histone deacetylase inhibitors. RESULTS: Preclinical and clinical antitumor activity has been observed. Toxicities include fatigue, myelosuppression, and cardiac abnormalities. CONCLUSIONS: Histone deacetylase inhibitors have shown promising activity in some solid tumors and hematologic malignancies.
Authors: Jehad Almaliti; Ayad A Al-Hamashi; Ahmed T Negmeldin; Christin L Hanigan; Lalith Perera; Mary Kay H Pflum; Robert A Casero; L M Viranga Tillekeratne Journal: J Med Chem Date: 2016-11-21 Impact factor: 7.446
Authors: Samantha M Gromek; James A deMayo; Andrew T Maxwell; Ashley M West; Christopher M Pavlik; Ziyan Zhao; Jin Li; Andrew J Wiemer; Adam Zweifach; Marcy J Balunas Journal: Bioorg Med Chem Date: 2016-08-24 Impact factor: 3.641
Authors: Tsoching Chen; Min-Jung Lee; Yeong Sang Kim; Sunmin Lee; Shivaani Kummar; Martin Gutierrez; Stephen M Hewitt; Jane B Trepel; Ira W Levin Journal: Anal Chem Date: 2008-07-24 Impact factor: 6.986